Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Novel targeted therapies of T cell lymphomas

Fig. 1

Targeted T cell lymphoma therapies mode of action. ADCC: Antibody-dependent cellular cytotoxicity, CD: cluster of differentiation antigens CDX: CD16, CD25, CD30, CD38, CD47, CD52, KIR3DL2 (CD158k), CCR4 (CD194), ICOS (CD278), CAMD1; CDY: CD4, CD5, CD7, CD30, HDAC: histone deacetylase, ALK: anaplastic lymphoma kinase, PI3K: phosphoinositide 3-kinases, BCL11B: B cell lymphoma/leukemia 11B

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us